DarioHealth (DRIO)
(Delayed Data from NSDQ)
$1.00 USD
-0.12 (-10.71%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $1.01 +0.01 (1.00%) 7:58 PM ET
1-Strong Buy of 5 1
F Value C Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.00 USD
-0.12 (-10.71%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $1.01 +0.01 (1.00%) 7:58 PM ET
1-Strong Buy of 5 1
F Value C Growth D Momentum F VGM
Zacks News
Zacks.com featured highlights include TAL Education, The RealReal, DarioHealth, HealthEquity and Energous
by Zacks Equity Research
TAL Education, The RealReal, DarioHealth, HealthEquity and Energous have been highlighted in this Screen of The Week article.
Bet on 5 Top-Ranked Stocks With Rising P/E for Stellar Gains
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios. These stocks include TAL Education Group (TAL), The RealReal (REAL), DarioHealth (DRIO), HealthEquity (HQY) and Energous (WATT).
DarioHealth Corp. (DRIO) Q2 Earnings Beat Estimates
by Zacks Equity Research
DarioHealth (DRIO) delivered earnings and revenue surprises of 120.69% and 17.37%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
KORU Medical Systems Inc. (KRMD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of 50% and 12.04%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of -17.24% and 3.81%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
DarioHealth Corp. (DRIO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
DarioHealth (DRIO) delivered earnings and revenue surprises of 66.10% and 3.23%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0% and 0.08%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
OPKO Health (OPK) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of -33.33% and 5%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of -20.69% and 8.83%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?